{"id":18575,"date":"2021-03-31T11:05:15","date_gmt":"2021-03-31T09:05:15","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=18575"},"modified":"2021-06-17T13:02:50","modified_gmt":"2021-06-17T11:02:50","slug":"bioinvent-slutfor-nyemissioner-om-drygt-15-miljarder-kronor-under-en-period-kortare-an-ett-ar","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/bioinvent-slutfor-nyemissioner-om-drygt-15-miljarder-kronor-under-en-period-kortare-an-ett-ar\/","title":{"rendered":"BioInvent slutf\u00f6r nyemissioner om drygt 1,5 miljarder kronor under en period kortare \u00e4n ett \u00e5r"},"content":{"rendered":"<p class=\"preamble\">BioInvent, ett f\u00f6retag i klinisk fas som fokuserar p\u00e5 att utveckla nya, first-in-class immunmodulerande antikroppar f\u00f6r cancerbehandling, har i mars 2021 slutf\u00f6rt en aktiekapitalsfinansering om mer \u00e4n 1,5 miljarder kronor under en period av tio m\u00e5nader.<\/p>\n<p>Aktiekapitalsfinanseringen bestod av en riktad nyemission i juni 2020 om ca 487 miljoner kronor i tv\u00e5 trancher, en f\u00f6retr\u00e4desemission (repair issue) om ca 139 miljoner kronor i juli 2020 och en riktad nyemission om ca 962 miljoner kronor i tv\u00e5 trancher som avslutades i mars 2021.<\/p>\n<p>Emissionslikviderna finansierar utbyggnaden av bolagets kliniska program. Investerare i de riktade emissionerna \u00e4r en rad internationella och svenska institutionella investerare, b\u00e5de befintliga och nya.<\/p>\n<p>BioInvent bitr\u00e4ddes av Mannheimer Swartling.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioInvent, ett f\u00f6retag i klinisk fas som fokuserar p\u00e5 att utveckla nya, first-in-class immunmodulerande antikroppar f\u00f6r cancerbehandling, har i mars 2021 slutf\u00f6rt en aktiekapitalsfinansering om\u2026<\/p>\n","protected":false},"author":9,"featured_media":17382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-18575","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":18575,"en":18578},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/18575"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=18575"}],"version-history":[{"count":4,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/18575\/revisions"}],"predecessor-version":[{"id":18581,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/18575\/revisions\/18581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/17382"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=18575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=18575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=18575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}